AlphaStocks

AMPH vs INVA

As of Sep 20, 2026, Amphastar Pharmaceuticals (AMPH) scores 7.5/10 and Innoviva (INVA) 4.8/10 on AlphaStocks' five-model composite, so AMPH scores higher.

AMPH

Amphastar Pharmaceuticals, Inc.

7.5

Strong Buy

$23.60

INVA

Innoviva, Inc.

4.8

Weak

$21.13

AMPH vs INVA: Which is the Better Investment?

Amphastar Pharmaceuticals, Inc. (AMPH) scores 7.5/10 while Innoviva, Inc. (INVA) scores 4.8/10 on AlphaStocks' composite model. Amphastar Pharmaceuticals, Inc. has the higher composite rating of Strong Buy.

This comparison is algorithmically generated and is not financial advice.

MetricAMPHINVA
Scores & Fundamentals
Composite Score7.5/104.8/10
RatingStrong BuyWeak
Price$23.60$21.13
P/E Ratio6.6
ROE24.8%
Market Cap$1B$2B
Fair Value
Dividend Yield
Sector Rank#4 of 168#118 of 168
Model Verdicts
PiotroskiAttractiveAttractive
BuffettAttractiveAttractive
GrahamAttractiveAttractive
LynchAttractiveStrong
GreenblattAttractiveStrong
View full AMPHanalysis →View full INVAanalysis →

Related comparisons

Compare any two stocks →

AMPH vs INVA: Which Stock Scores Higher?

Amphastar Pharmaceuticals, Inc. (AMPH) and Innoviva, Inc. (INVA) are both in the Health Care sector. AMPH currently leads with a composite score of 7.5/10 (Strong Buy) compared to INVA's 4.8/10 (Weak).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer